Australia's best minds in melanoma research converge on Melbourne
8 October 2018
The 2018 Australasian Melanoma Conference, held in Melbourne over the weekend, focussed on the integration of research and clinical care.
Melanoma Institute Australia’s Medical Directors, Professor Georgina Long and Professor Richard Scolyer, led the large contingent from MIA. In the targeted therapies session, Professor Long asked “where to next?”, while Professor Scolyer spoke on the challenges associated with borderline lesions and, in the Saturday lunchtime plenary session, discussed predicting patient outcomes.
Among the team of MIA clinicians was Professor Graham Mann who presented insights from the Australian Melanoma Genome Project and the Australian Melanoma Clinical Outcomes Registry. Associate Professor Pascale Guitera spoke on dermoscopy and provided an educational course on confocal microscopy, and Associate Professor Jon Stretch, Professor Angela Hong, Professor Peter Hersey and research affiliates Professor Nick Hayward and Professor Helen Rizos all chaired sessions.
A joint presentation from Professor Andrew Spillane and Associate Professor Alex Menzies in the management of loco-regional disease session provided both surgical and medical approaches to regional disease. Professor Diona Damian debated topical and injectable therapies for cutaneous melanoma, and Associate Professor Robyn Saw discussed follow-up and investigation for high-risk melanoma patients in the supportive care and survivorship session. A clinician’s perspective of The National Melanoma Guidelines from Professor John Thompson rounded out the weekend.
A highlight of the conference was the Consumer Breakfast, where a panel of people affected by melanoma, including MIA’s Jay Allen, discussed solariums, early detection, and the importance of support and routines after diagnosis. They shared stories, hope, and the importance of fundraising. “We need to keep raising funds, by organising events in local areas or supporting larger fundraising campaigns, because without funding, we don’t have research,” Mr Allen said.
Photograph: Australasian Melanoma Conference
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.